Veeva Systems (VEEV) Scheduled to Post Quarterly Earnings on Wednesday

Veeva Systems (NYSE:VEEV) is scheduled to be announcing its earnings results after the market closes on Wednesday, August 28th. Analysts expect the company to announce earnings of $1.53 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Veeva Systems (NYSE:VEEV) last announced its earnings results on Thursday, May 30th. The technology company reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.10. Veeva Systems had a return on equity of 12.74% and a net margin of 22.34%. The firm had revenue of $650.35 million during the quarter, compared to analysts’ expectations of $641.73 million. On average, analysts expect Veeva Systems to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Veeva Systems Stock Up 1.1 %

VEEV opened at $199.25 on Monday. The stock has a market cap of $32.21 billion, a P/E ratio of 58.78, a PEG ratio of 1.93 and a beta of 0.80. Veeva Systems has a 52-week low of $162.72 and a 52-week high of $236.90. The business has a fifty day moving average of $186.60 and a 200 day moving average of $202.28.

Insiders Place Their Bets

In other news, CFO Timothy S. Cabral sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $184.33, for a total value of $2,764,950.00. Following the completion of the transaction, the chief financial officer now owns 8,391 shares of the company’s stock, valued at $1,546,713.03. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CFO Timothy S. Cabral sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $184.33, for a total transaction of $2,764,950.00. Following the completion of the sale, the chief financial officer now owns 8,391 shares in the company, valued at $1,546,713.03. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jonathan Faddis sold 2,353 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $200.00, for a total transaction of $470,600.00. Following the completion of the transaction, the senior vice president now owns 9,035 shares in the company, valued at $1,807,000. The disclosure for this sale can be found here. 10.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $260.00 target price on shares of Veeva Systems in a report on Monday, July 15th. Bank of America lowered their price objective on Veeva Systems from $240.00 to $204.00 and set a “neutral” rating for the company in a research report on Friday, May 31st. Barclays dropped their price target on Veeva Systems from $245.00 to $220.00 and set an “overweight” rating on the stock in a research note on Friday, May 31st. UBS Group decreased their price target on shares of Veeva Systems from $235.00 to $185.00 and set a “neutral” rating for the company in a report on Friday, May 31st. Finally, Canaccord Genuity Group lowered their price target on Veeva Systems from $220.00 to $210.00 and set a “hold” rating for the company in a research report on Friday, May 31st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $228.27.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.